Limited Benefits Halt Enrollment in Hematopoietic Stem Cell Transplantation Trial for Stiff-Person Syndrome
Should There Be More to Come?
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Stiff-person syndrome (SPS) is an autoimmune disease characterized by stiffness of truncal and proximal limb muscles due to co-contracture of agonist and antagonist muscles resulting in hyperlordosis, difficulty bending, slow gait, and statue-like appearance; episodic spasms precipitated by unexpected auditory, tactile, visual, or stressful stimuli; and task-specific phobias.1,2 High-titer autoantibodies against glutamic acid decarboxylase (GAD)–65, the rate-limiting enzyme for GABA synthesis, or glycine receptors are detected in most patients, denoting impaired inhibitory neurotransmission causing excitotoxicity, spasms, and stiffness.1–3 High GAD titers are also seen, or overlap with, autoimmune epilepsy, encephalitis, cerebellar ataxia, and myoclonus, forming the GAD spectrum disorder.2,3 SPS responds to GABA-enhancing drugs (diazepam, baclofen, anticonvulsants) and certain immunotherapies.1–4 A placebo-controlled trial with IV immunoglobulin (IVIg) showed significant improvements in 70% of patients,5 but a randomized controlled trial with rituximab did not reach significance due to strong placebo effect, although 35% of patients improved.6 Plasmapheresis, corticosteroids, and immunosuppressants variably show limited benefits.2–4 Patients poorly responding to these therapies may become permanently impaired, requiring walkers or wheelchairs. Additional immunotherapies are therefore welcome.
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the author, if any, are provided at the end of the editorial.
See page 245
- © 2020 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.